Shilpa Gupta, MD

Shilpa Gupta, MD, associate professor of Genitourinary Oncology at the Cleveland Clinic, explains the rationale for adding androgen receptor (AR) therapy to cisplatin- and gemcitabine-based chemotherapy.

AR is overexpressed in bladder cancer, and preclinical studies have shown that AR is a good target to inhibit when treating patients with bladder cancer. Specifically, AR inhibitors prevent tumor growth and disease progression. There is also research that shows that AR is sensitive to cisplatin, according to Gupta. These early studies served as the rationale for a study in which enzalutamide (Xtandi) was added to cisplatin and gemcitabine.

phase I study was conducted with the combination of enzalutamide plus cisplatin and gemcitabine

. In the dose-finding portion of the study, patients received either enzalutamide 80mg or 160mg along with the standard doses of cisplatin and gemcitabine.

No dose-limiting toxicities were observed in the dose-finding portion, and the study moved on to the dose-expansion phase.

Videos

Shilpa Gupta, MD, explains the rationale for adding androgen receptor therapy to cisplatin- and gemcitabine-based chemotherapy.

Rationale for Targeting Androgen Receptor Overexpression in Bladder Cancer 

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the current role of immunotherapy in treating patients with bladder cancer and how biomarkers have become an unmet need.

Although immunotherapy options have been an improvement since there weren&rsquo;t any new therapies added to the bladder cancer treatment paradigm for the last 40 years in this population, says Gupta, only 20% to 25% of patients respond to immunotherapy. Biomarkers, however, can identify patients that can be spared the risk of disease progression and financial toxicities by determining earlier on the patients that likely will not respond to single-agent checkpoint inhibitors. Gupta urges that we need to do a better job going forward at finding the patients who likely will or will not respond.

Shilpa Gupta, MD, discusses the current role of immunotherapy in treating patients with bladder cancer and how biomarkers have become an unmet need.

Exploring the Role of Biomarkers in Patient Selection for Immunotherapy in Bladder Cancer 

Shilpa Gupta, MD, genitourinary oncologist at the University of Minnesota, discusses the progress made with immunotherapy in bladder cancer over the last few years.

There has been many advances in terms of immunotherapy in this patient population, and many trials are combining chemotherapy with these agents in the hopes of improving overall survival and gaining more durable responses, says Gupta. Later this year, we will learn more about these data as they read out.

Shilpa Gupta, MD, discusses the progress over the last few years in bladder cancer.

Highlighting Immunotherapy Progress in Bladder Cancer

Shilpa Gupta, MD, assistant professor in the Hematology, Oncology, and Transplantation Division at the University of Minnesota, discusses the potential for triplet regimens in the treatment of patients with renal cell carcinoma (RCC).

According to Gupta, preliminary safety data is needed for triplet regimens in RCC. Data in different tumor types has shown that combinations may be more effective, but not as safe.

<br />
Shilpa Gupta, MD, assistant professor in the Hematology, Oncology, and Transplantation Division at the University of Minnesota, discusses the potential for triplet regimens in the treatment of patients with renal cell carcinoma.

Expert Insights on the Potential for Triplet Regimens in RCC

Shilpa Gupta, MD, assistant professor of Medicine in the Hematology, Oncology, and Transplantation Division, University of Minnesota, discusses phase Ib and phase II studies of pembrolizumab (Keytruda) with bevacizumab (Avastin) for the treatment of metastatic renal cell carcinoma (mRCC) during the 2018 ASCO Annual Meeting.

Shilpa Gupta, MD, assistant professor of Medicine in the Hematology, Oncology, and Transplantation Division, University of Minnesota, discusses phase Ib and phase II studies of pembrolizumab (Keytruda) with bevacizumab (Avastin) for the treatment of metastatic renal cell carcinoma during the 2018 ASCO Annual Meeting.

Shilpa Gupta, MD | Authors

Articles

Rationale for Targeting Androgen Receptor Overexpression in Bladder Cancer

Exploring the Role of Biomarkers in Patient Selection for Immunotherapy in Bladder Cancer

Highlighting Immunotherapy Progress in Bladder Cancer

Expert Insights on the Potential for Triplet Regimens in RCC

Promising Results for Pembrolizumab With Bevacizumab in mRCC